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Abstract
Background: Burkholderia pseudomallei is the causative agent of melioidosis, a disease of significant morbidity and mortality
in both human and animals in endemic areas. There is no vaccine towards the bacterium available in the market, and the
efficacy of many of the bacterium’s surface and secreted proteins are currently being evaluated as vaccine candidates.
Methodology/Principal Findings: With the availability of the B. pseudomallei whole genome sequence, we undertook to
identify genes encoding the known immunogenic outer membrane protein A (OmpA). Twelve OmpA domains were
identified and ORFs containing these domains were fully annotated. Of the 12 ORFs, two of these OmpAs, Omp3 and Omp7,
were successfully cloned, expressed as soluble protein and purified. Both proteins were recognised by antibodies in
melioidosis patients’ sera by Western blot analysis. Purified soluble fractions of Omp3 and Omp7 were assessed for their
ability to protect BALB/c mice against B. pseudomallei infection. Mice were immunised with either Omp3 or Omp7,
subsequently challenged with 1610
6 colony forming units (cfu) of B. pseudomallei via the intraperitoneal route, and
examined daily for 21 days post-challenge. This pilot study has demonstrated that whilst all control unimmunised mice died
by day 9 post-challenge, two mice (out of 4) from both immunised groups survived beyond 21 days post-infection.
Conclusions/Significance: We have demonstrated that B. pseudomallei OmpA proteins are immunogenic in mice as well as
melioidosis patients and should be further assessed as potential vaccine candidates against B. pseudomallei infection.
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Introduction
Burkholderia pseudomallei is a gram-negative facultative anaerobic
motile bacillus that is the causative agent of melioidosis, an infectious
disease resulting in significant morbidity and mortality for both
humans and animals in endemic regions such as Southeast Asia and
northern Australia [1,2]. Melioidosis can present in many clinical
forms, from acute pneumonia or septicaemia to chronic and
subclinical forms and this poses a great challenge in rapid and
accurate diagnosis of the disease [3]. Furthermore, therapy is
complicated by antibiotic resistance in many clinical isolates,resulting
in frequent relapse of patients and the mortality rate of patients with
septic shock is approximately 80–95% despite treatment with
ceftazideme, imipenem or meropenem [2]. Therefore, prevention,
rather than cure of melioidosis, is critical.
Various vaccination strategies have been extensively explored.
Recent work demonstrated significant protection in animal models
following vaccination with attenuated strains of B. pseudomallei [4].
Attenuated strains for vaccination would require proof of
avirulence as even ara
+ B. thailandensis, which is generally
considered avirulent, can also cause clinical infection in humans
[5], an important implication for vaccine research. Other
approaches investigated include the use of dendritic cells as a
delivery vector to generate cell-mediated immunity [6], conjugate
vaccines of capsular polysaccharides and O-polysaccharide [7,8]
and the DNA vaccine against fliC flagellin structural gene [9].
With the advances in whole-genome sequencing and bioinformatics,
one can use the genomic information to discover novel antigens which
may have been missed by conventional methods. In this study, we
adopted a bioinformatics-based approach to identify potential
protective antigens in B. pseudomallei by using the genome information
of B. pseudomallei K96243 made available by The Wellcome Trust
Sanger Institute. We selected putative outer membrane protein A
(OmpA) as OmpAs are often involved in bacterial virulence and
immunity, have good immunogenic properties and are therefore,
important vaccine candidates [10,11]. Indeed, OmpAs from Porphyr-
omonas gingivalis, a periodontal pathogen implicated in chronic
periodontitis has been demonstrated to confer a high level of protection
in the P. gingivalis murine lesion model [12]. In this study, we sought to
determine the immunogenic properties of B. pseudomallei recombinant
OmpAs and their ability to protect mice from B. pseudomallei infection.
Our data demonstrate that two recombinant OmpAs evaluated were
immunogenic in mice and show potential as candidate vaccine targets.
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Identification of putative B. pseudomallei OmpA genes
We performed a BLASTP search using the conserved OmpA
domain sequence (PF00691) as the query sequence and identified
14 open reading frames (ORFs) coding for proteins containing the
OmpA conserved domain in the B. pseudomallei K96243 reference
genome sequence. Of these 14 proteins, 13 hits had an E-value of
1e
24 or better, however, ORF 13 was not included for further
studies as it was annotated as a putative cytochrome C oxidase
(Table 1). Subsequently, 12 ORFs coding for OmpA-like proteins
were selected for further analysis. Conservation of the OmpA
domain sequence at the C-terminal of all 12 B. pseudomallei OmpA
sequences as well as in 5 experimentally verified OmpAs [Klebsiella
pneumoniae OmpA (ABR76422), Escherichia coli OmpA
(NP_415477.1), P. gingivalis OmpA PG33 (AF175715), P. gingivalis
OmpA PG32 (AF175714) and Neisseria meningitidis OmpA RmpM
(YP_001599860)] is shown in Fig. 1. Residues previously proposed
to be involved in N. meningitidis RmpM direct (D45, Y53, R67, and
R140) and indirect (F2, G42, G49, N54, L63, G102) interactions
with peptidoglycans are present in B. pseudomallei OmpA sequences
and are denoted as asterisks and dots in Fig. 1. In addition, the
multiple sequence alignment demonstrated that Omp3 clustered
together with E. coli OmpA and K. pneumoniae OmpA while Omp7
clustered closely with P. gingivalis OmpAs. N-terminal sequences,
on the other hand, were highly heterogeneous. Analysis of the
global sequence similarity and calculated percentage identity
demonstrated that both Omp3 and Omp7 revealed considerable
similarity to reference proteins (Fig. 2). Omp3 was 40% identical
to both E. coli and K. pneumoniae OmpA proteins while Omp7 was
21–23% identical to P. gingivalis OmpA proteins.
Cloning, protein expression and purification of OmpA
Primers were designed to amplify the 12 OmpA-coding genes
from the local clinical isolate, B. pseudomallei D286. The size of the
predicted ORFs ranged from 513–1677 bp. The amplicons were
successfully cloned into the pET101/D-TOPO expression vector
for recombinant protein production. The full-length sequences of
the inserts were verified by DNA sequencing (data not shown).
Expression of 12 B. pseudomallei recombinant outer membrane
proteins was carried out and various parameters such as induction
time, isopropyl b-D-1-thiogalactopyranoside (IPTG) concentration
and growth temperature, were optimized. Eight recombinant
proteins were successfully expressed, of which 6 were soluble and 2
were insoluble proteins. We attempted to re-solubilise both
insoluble recombinant proteins using high concentrations of the
denaturants urea or guanidinium hydrochloride followed by
dialysis. However, neither strategy resulted in sufficient amounts
of soluble protein for subsequent analysis; thus, further studies on
the OmpA proteins were limited to 6 soluble recombinant
proteins. All 6 soluble fusion proteins were successfully detected
with anti-His tag antibody by Western blot analysis (Fig. 3A). The
proteins range in size from 22.5 kDa to 65 kDa corresponding to
the predicted ORF. The recombinant proteins were reacted with
rabbit antiserum raised against B. pseudomallei whole cells. All 6
recombinant proteins reacted with rabbit antiserum, but the
degree of reactivity varied with the strongest reactivity observed
with Omp3 and Omp7 (Fig. 3B). Subsequently, all 6 recombinant
proteins were also reacted with melioidosis patients’ sera. We
pooled sera from five patients with different disease presentations
in order to detect a spectrum of reactive antigens. Pooling takes
advantage of the different immune responses presented by the
hosts to the pathogen throughout the course of infection. Among
the 6 recombinant proteins tested, Omp10 did not show any
reactivity while Omp6 reacted relatively weakly. Both Omp3 and
Omp7 demonstrated strong reactivity towards pooled patients’
sera (Fig. 3C). None of the 6 recombinant proteins were
recognised by antibodies from Legionella patients’ sera (B.
pseudomallei-negative) (data not shown). A distinct band with
slightly lower molecular weight was also detected for recombinant
Omp3 and Omp6. It is presently unknown if the multiple bands
correspond to different isoforms of Omp3 and Omp6 or was a
result of proteolytic breakdown.
Table 1. Putative OmpA genes identified by BLASTP analysis using the OmpA domain sequence (below) as the query against the
B. pseudomallei K96243 reference genome sequence.
Designation Sanger annotation BLAST score Probability (N)
Omp1 putative OmpA family transmembrane protein 191 6.6e-17
Omp2 putative outer membrane protein 177 4.2e-15
Omp3 OmpA outer membrane protein precursor 211 5.0e-19
Omp4 OmpA family protein 171 8.7e-15
Omp5 putative exported protein 172 1.3e-14
Omp6 OmpA family membrane protein 173 5.2e-14
Omp7 putative OmpA family lipoprotein 161 1.0e-13
Omp8 OmpA family membrane protein 150 1.0e-11
Omp9 OmpA family protein 160 2.3e-13
Omp10 OmpA family membrane protein 125 8.8e-10
Omp11 OmpA family membrane protein 146 2.6e-11
Omp12 OmpA family membrane protein 88 7.0e-05
ORF13 putative cytochrome c oxidase 125 6.9e-09
ORF14 hypothetical protein 81 0.00029
Conserved OmpA domain sequence used as a query sequence (PF00691):
LFDFDKATLKPEQQQLLDAIADLLKAIPPDNRVIVEGHTDSRPIGSDEYPSNQALSERRADSVADYLVSKGGVPADRISAVGYGESKPIASNKTEEGRAKNR.
doi:10.1371/journal.pone.0006496.t001
B. pseudomallei OmpA
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recombinant OmpA
Based on their strong reactivity towards anti-sera from B.
pseudomallei infected humans and animals in addition to higher
sequence similarity to known immunogenic OmpAs from other
gram negative bacteria, Omp3 (Genbank accession number
FJ746559) and Omp7 (Genbank accession number FJ746560)
were selected to induce an antibody response and establish the
ability of these two recombinant proteins to protect against B.
pseudomallei infection in mice. To assess the immunogenicity of the
recombinant Omp3 and Omp7, sera were collected and pooled
from immunised mice prior to B. pseudomallei challenge, and tested
for reactivity with purified OmpA by ELISA. The specific
antibodies against recombinant Omp3 and Omp7 were observed
in immunised mice with several dilutions screened, but, not in the
pre-immunised sera (P,0.05) (Fig. 4). The absorbance value for
anti-Omp7 antibodies was higher at all dilutions tested compared
to anti-Omp3 antibodies, especially at higher dilutions.
To identify the type of immune response induced, we
determined specific IgG subclasses (IgG1, IgG2a, IgG2b) and IgM
antibody titres by ELISA. The results indicated significantly higher
titres (P,0.05) of IgG1, IgG2a, IgG2b and IgM antibodies were
produced in mice immunised with recombinant Omp3 and Omp7
when compared to antibody titres in the pre-immunised sera from
the same mice. Immunisation with Omp3 induced higher
antibody titres in all the antibody isotypes when compared to
Omp7 immunised mice but the difference was not significant. The
predominant Ig subclass elicited by Omp3 and Omp7 immuni-
sation was IgG2a followed by IgG2b and to a lesser extent, IgG1.
The ratio of IgG2a/IgG1 was 1.2 in Omp3 immunised mice and
1.3 in Omp7 immunised mice, respectively (Fig. 5).
From our previous work, the LD50 for the local clinical isolate used
in this study, D286, was calculated to be 10
5 cfufollowing infection of
BALB/c mice via an intraperitoneal route. Similar LD50 values were
previously reported for other B. pseudomallei clinical isolates [13] and
we settled on a challenge dose of 106LD50 as recommended by Ulett
et al. [14]. The challenge dose of 106LD50 is equivalent to LD100,
wherebythedoseshouldcause100%deathoftheinfectedanimalsby
the end of the observation period. Thus, any reduction in the
mortality figures as a result of the immunisation would indicate the
potential protective efficacy of these recombinant proteins.
For the control group of mice (n=3) immunised with E. coli cells
in adjuvant and subsequently challenged with B. pseudomallei, one
mouse succumbed at 1-day post challenge, the second on day 6
and the last mouse died on day 9 with a median survival of 6 days
(Fig. 6). For mice immunised with Omp3, one mouse (out of 4)
died on day 2 and the second on day 4 (2/4) with a median
survival of 13 days, while for mice immunised with Omp7, one
mouse died on day 2 and the second on day 15 (2/4) with a
median survival of 18 days. The remaining two mice from each
group immunised with either Omp3 or Omp7 survived beyond 21
days post-challenge (Fig. 6). Immunisation with both recombinant
proteins resulted in the prolonged median survival (7–12 days) in
immunised animals compared to the control group.
In this pilot experiment, both recombinant Omp3 and Omp7
demonstrated protection in mice, but the degree of protection
provided by immunisation using a single protein was incomplete
(50%). The challenged survivors displayed significant splenomeg-
aly and multiple abscess formation, demonstrating incomplete
bacterial clearance from the system (data not shown).
Discussion
B. pseudomallei is an intracellular pathogen and is known to
survive and multiply within both phagocytic and non-phagocytic
host cells and may be able to spread directly from cell to cell [15].
Thus, the nature of this bacterium highlights the need to generate
cell-mediated immunity to combat infection. In an attempt to
identify proteins capable of inducing a cell-mediated immune
response, we selected putative B. pseudomallei proteins homologous
to immunogenic OmpA to demonstrate proof-of-concept. We
adopted a bioinformatics-based approach, and by utilising the
reference genome sequence of B. pseudomallei K96243, we identified
12 putative OmpA genes in the genome. These genes contain the
conserved OmpA domain at the C-termini (Fig. 1) while their N-
terminal sequences share little similarity, another characteristic of
OmpAs as they are generally heterogeneous at the N-terminal [16].
The C-terminal domain contains conserved residues previously
proposed to be important for protein function and interaction with
peptidoglycans in N. meningitidis [17]. Some residues may interact
directly with peptidoglycans while others may have an indirect
interact with peptidoglycans by stabilising residues involved in the
direct interaction. All identified residues were well conserved in B.
pseudomallei OmpAs, suggestingthattheymay playsimilarrolesinB.
pseudomallei OmpA interaction with peptidoglycans for maintenance
of membrane and cell morphology.
OmpAs are known to be involved as virulence factors in bacterial
pathogenesis and are capable of inducing both humoral and
Figure 1. Multiple sequence alignment (C-termini) of predicted amino acid sequences of B. pseudomallei D286 OmpA. The predicted
amino acid sequences of 12 B. pseudomallei OmpAs together with 5 experimentally verified immunogenic OmpAs were aligned. The experimentally
verified OmpAs used for the alignment: E. coli OmpA (NP_415477.1), KpmOmpA - K. pneumoniae OmpA (ABR76422), PG33 - P. gingivalis OmpA
(AF175715), PG32 - P. gingivalis OmpA (AF175714), RmpM–N. meningitidis OmpA (YP_001599860). The residues implicated for their role in the
interactions with peptidoglycans are indicated (asterisks - direct interaction; dots - indirect interaction).
doi:10.1371/journal.pone.0006496.g001
B. pseudomallei OmpA
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the design of vaccines for bacterial infections caused by Gram
negative bacteria suchasVibrio cholerae [10],K.pneumoniae[19] andP.
gingivalis [12] and promising data from animal models have been
reported. Thus, we expressed 6 soluble recombinant B. pseudomallei
OmpAs to assess their immunogenicity and evaluate the potential
protective efficacy in an animal model of melioidosis. The observed
presence of antibodies towards this class of membrane protein in
both the melioidosis animal model as well as human patients
implicates a functional role for OmpA during active B. pseudomallei
infection. Indeed, evidence indicates that OmpA is a determinant of
bacterial virulence and that it is a major target of the mammalian
host cell defence [20,21]. The differences in immunoreactivity
demonstrated by B. pseudomallei OmpAs may somewhat correlate to
the sequence similarity of these OmpAs to experimentally verified
immunogenic OmpAs. The strongly immunoreactive Omp3 and
Omp7 were clustered together with known immunogenic OmpAs
(from E. coli, K. pneumonia and P. gingivalis) whereas weakly reactive
proteins (Omp6 and Omp10) were not as closely related. The
percentage of sequence identity observed between Omp3/Omp7
and the reference proteins was moderate and predominantly at the
C-terminal domain, however, they showed considerable global
Figure 2. Multiple sequence alignment of Omp3 and Omp7 with known immunogenic OmpAs. Omp3 was aligned with E. coli OmpA
(NP_415477.1) and K. pneumoniae OmpA (ABR76422) while Omp7 was aligned with P. gingivalis OmpAs PG33 (AF175715) and PG32 (AF175714).
doi:10.1371/journal.pone.0006496.g002
B. pseudomallei OmpA
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transferred onto a nitrocellulose membrane and reacted with (A) monoclonal anti-histidine tag antibody conjugated with HRP. The expected protein
sizes for Omp3, 4, 5, 6, 7 and 10 are 27, 27.5, 34, 65, 22.5 and 24.5 kDa respectively. Molecular weight sizes (kDa) of the broad range marker are
indicated in the left panel. Among 6 recombinant OmpA proteins, Omp3 and Omp7 reacted strongly with (B) rabbit anti-B. pseudomallei sera and (C)
pooled melioidosis patients’ sera compared to other Omps. Lane 1; Omp3, lane 2; Omp4, lane 3; Omp5, lane 4; Omp6, lane 5; Omp7, lane 6; Omp10.
doi:10.1371/journal.pone.0006496.g003
B. pseudomallei OmpA
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at the structural level when they are exposed to the host immune
system. Furthermore, conservation of the C-terminal domain
sequence is important since the C-terminal domain of E. coli OmpA
is known to contain the immunodominant epitope and is efficiently
recognised by antibodies formed during the course of infection [22].
Similar immunodominant epitope(s) may be better conserved in
Omp3 and Omp7 than in the other B. pseudomallei OmpAs and/or
exposed more efficiently, leading to better recognition by antibodies
from infected individuals.
Vaccine development for melioidosis is made difficult because
B. pseudomallei is an intracellular pathogen that can successfully
evade the host immune system for an extended period of time.
Effective vaccination against this pathogen is therefore required to
elicit a cytokine-mediated cellular response so as to combat
potential disease recurrence [23]. Various approaches have been
undertaken towards the development of effective vaccines against
B. pseudomallei infection in animal models. Those investigated
include heat-killed or live attenuated mutants of B. pseudomallei,
polysaccharides and a DNA-vaccine coding for the fliC flagellin
structural gene [4,7–9]. These studies demonstrated a significant
protection against B. pseudomallei infection in immunised animal
models, however, the level of protection varied depending on the
different vaccine strategies. For example, immunisation with
attenuated mutants of B. pseudomallei resulted in 60% survival rate
at 35 days post challenge in immunised mice [4] while DNA-
vaccination protected 85% of vaccinated mice up to 7 days post
infection [9] but the observation period was limited. Active
immunisation with B. pseudomallei lipopolysaccharide resulted in
50% survival at day 35 post challenge in immunised mice [8].
Thus, data from the present pilot study is generally comparable to
these previously reported efficacies whereby immunisation with
recombinant Omp3 or Omp7 could be seen to be as effective as
immunisation with lipopolysaccharide in murine models of
melioidosis. Furthermore, our assessment of polyclonal antibody
isotypes in the sera from Omp3- and Omp7-immunised mice
indicated a predisposition towards a Th1-driven immune response
as demonstrated by an IgG2a/IgG1 ratio of .1 [24]. Both
recombinant proteins demonstrated similar potential protective
efficacy, however, Omp7 appeared to be more efficient in
inducing a higher titre of anti-Omp7 antibodies and higher
IgG2a/IgG1 ratio. This may have contributed to the improvement
of the median survival in Omp7-immunised mice when compared
to Omp3-immunised mice. However, challenged survivors were
unable to clear the infection and a chronic infectious status was
evidently present, whereby mice eventually succumbed to the
infection. Such findings are consistent with previously reported
studies that immunisation strategies alone are not sufficient to
protect animals from infection. Furthermore, recombinant anti-
gens as vaccination candidates typically induce strong humoral
antibodies but may be hampered in their ability to induce the
cellular-mediated immune response [25]. Eradication of B.
pseudomallei has been proposed to be dependent on the induction
of a Th1 type immune response at the onset of melioidosis [6].
This is because in the presence of protective humoral antibodies,
B. pseudomallei is still able to invade epithelial or phagocytic cells,
resulting in a long term intracellular latent infection in the infected
individuals before relapse occurs many years later [26,27].
Figure 4. Screening of OmpA-specific IgG in immunised BALB/c mice. Mice were immunised with 50 mg of recombinant Omp3 or Omp7. The
sera were collected (n=4) prior to and after immunisation and pooled. The levels of OmpA-specific IgG were analysed by ELISA. The presence of
specific antibodies to recombinant Omp3 (closed triangles) and Omp7 (closed squares) proteins was observed in sera from immunised mice but not
in pre-immunised sera (open triangles for Omp3 pre-immunised sera and open squares for Omp7 pre-immunised sera) (P,0.05). Data represent the
mean absorbance (OD450nm)6SEM.
doi:10.1371/journal.pone.0006496.g004
B. pseudomallei OmpA
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has been proposed to be effective in inducing significant levels of
protective immune response against heterologous strains of B.
pseudomallei by eliciting strong cell-mediated immune responses and
lower but adequate levels of antibody responses [28]. Although the
use of cultured DCs as a human vaccine candidate is simply not
viable, a vaccine strategy that actively targets DCs is feasible by
means of a formulation carrying recombinant B. pseudomallei
antigens and Toll-like receptor (TLR) ligands. B. pseudomallei
binding to its known receptor, TLR2, would activate the DCs,
initiating the process of antigen uptake, processing and presenta-
tion required for the generation of protective immune responses.
Recombinant OmpAs from this study could be good candidate
antigens for coupling to DCs.
In summary, this study has demonstrated that by using publicly
available bacterial genome sequence information, we successfully
identified two immunogenic antigens, Omp3 and Omp7.
Although more extensive studies are required, data from this pilot
experiment have demonstrated the promising protective efficacy of
B. pseudomallei OmpAs against an animal model of melioidosis.
Materials and Methods
Ethics statement
All animal experiments were performed in accordance with the
animal ethics guideline compiled by Universiti Kebangsaan
Malaysia Animal Ethics Committee (UKMAEC). Animals were
maintained under specific-pathogen-free conditions and on a 12-h
Figure 5. Analysis of OmpA-specific polyclonal antibody isotypes in immunised BALB/c mice. Mice were immunised with 50 mgo f
recombinant Omp3 or Omp7. The sera were collected (n=4) prior to and after immunisation and pooled. The levels of IgG subclasses and IgM were
determined by ELISA. Data represent the mean absorbance (OD450nm)6SEM. The IgG2a/IgG1 ratio of Omp3-immunised mice is 1.2 while for Omp7-
immunised mice, the ratio is 1.3. Open bars represent pre-immunised sera, grey bars represent anti-Omp3 antibody and black bars represent anti-
Omp7 antibody.
doi:10.1371/journal.pone.0006496.g005
Figure 6. Survival of BALB/c mice immunised with recombinant
Omp3 or Omp7 and challenged with B. pseudomallei. Mice were
immunised with either Omp3 (open triangles) or Omp7 (open squares)
prior to challenge with 1610
6 cfu B. pseudomallei by the i.p. route of
infection. Both groups immunised with either Omp3 or Omp7 displayed
50% survival rate up to 21 days post-infection. All the control mice
(closed squares) received E. coli BL21 (DE3) cells in FIA followed by
challenge, and died by day 9 post-challenge.
doi:10.1371/journal.pone.0006496.g006
B. pseudomallei OmpA
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were obtained from the Universiti Kebangsaan Malaysia Animal
House Facility. The rabbits were housed in individual cages and
had free access to food and water during the study. The mice were
provided with pelleted protein-enriched diet and water ad libitum.
In silico genome analysis and multiple sequence
alignment
The conserved OmpA domain sequence PF00691 (Table 1) was
used as a query sequence to perform BLASTP [29] analysis
against the annotated genome sequence of B. pseudomallei clinical
strain K96243 deposited at http://www.sanger.ac.uk/cgi-bin/
blast/submitblast/b_pseudomallei. The sequences containing the
conserved OmpA domain were selected using a cut-off threshold
of 1e
24. Subsequently, full ORFs of these genes were determined
using Artemis [30]. Multiple sequence alignment of B. pseudomallei
OmpA sequences together with the 5 experimentally verified
OmpAs from other gram negative bacteria [K. pneumoniae OmpA
(ABR76422), E. coli OmpA (NP_415477.1), P. gingivalis OmpA
PG33 (AF175715), P. gingivalis OmpA PG32 (AF175714) and N.
meningitidis OmpA RmpM (YP_001599860)] was performed using
ClustalW [31]. The percentage identity between the predicted
amino acid sequences of B. pseudomallei OmpAs and immunogenic
OmpAs from other bacteria was calculated using Jalview [32].
Bacterial strain and preparation of genomic DNA
The B. pseudomallei strain D286 was previously isolated from a
melioidosis patient at the Kuala Lumpur Hospital [33]. A stock
culture of this strain was obtained from the Pathogen Laboratory,
Faculty of Science and Technology, Universiti Kebangsaan
Malaysia. Genomic DNA was extracted according to the standard
protocol [34] with modification. Briefly, B. pseudomallei strain D286
was grown at 37uC in Brain Heart Infusion broth (Pronadisa,
Spain) and then plated on Ashdown selective agar plates. A single
colony was inoculated into fresh Brain Heart Infusion broth and
grown overnight at 37uC, following which the bacterial cells were
harvested and the cell pellet was dissolved in TE buffer (1 mM
Tris-Cl, pH 7.5, 1 mM EDTA). The pellet was treated with
Proteinase K at a final concentration of 25 mg/ml and 10% SDS
(Amresco, USA) and incubated at 37uC for one hour. CTAB-
NaCl (10% CTAB (Sigma, USA), 0.7 M NaCl) was added and the
incubation was continued at 65uC for 20 min. Purification of
genomic DNA was carried out according to the standard phenol
chloroform method and precipitated using 0.6 V of isopropanol.
Amplification of B. pseudomallei OmpA genes and
cloning
Primer sequences used for amplification of the twelve ORFs
from the B. pseudomallei strain D286 genome were designed based
on the 12 annotated ORFs and are listed in Table 2. The forward
primers contained an additional CACC sequence at the 59-end to
allow direct cloning into the expression vector. PCR was
conducted in a final volume of 50 ml that contained 5 ml1 0 6
Expand High Fidelity reaction buffer with 15 mM MgCl2 (Roche,
Germany), 1 ml B. pseudomallei genomic template, 1 ml deoxynu-
cleotide mix (10 mM each of dNTP) (Promega, USA), 1 ml each of
forward and reverse primers (25 pmoles each), 5 U of Expand
High Fidelity enzyme mix (Roche, Germany) and 40.25 mlo f
MilliQ water. Amplification was performed under the following
conditions; 1 cycle of 95uC for 5 min; 10 cycles of 94uC for 15 s,
55uC for 30 s, and 72uC for 1 min; 20 cycles of 94uC for 15 s,
55uC for 30 s and 72uC for 1 min with 5 s cycle elongation for
each successive cycle for the final step; and 1 cycle of 72uC for
7 min. To achieve high efficiency and regulation for cloning and
expression in an E. coli expression system, PCR products were
cloned into pET101/D-TOPOH according to the manufacturer’s
recommendations (Invitrogen, USA). The gene orientation and
sequence fidelity was verified by DNA sequencing.
Recombinant OmpA protein production and purification
Transformation of host BL21 Star (DE3) cells was performed
according to the manufacturer’s recommendations (Invitrogen,
USA). The positive control used for expression was E. coli BL21
Star (DE3) transformed with pET-101-LacZ (Invitrogen, USA).
The colonies were cultured overnight and used to inoculate fresh
LB medium supplemented with carbenicillin (50 mg/ml) (Phyto-
technology Laboratories, USA). At OD600nm=0.5–0.6, expression
was induced with 1 mM IPTG (Promega, USA) for 4 hr at 30uC.
At the end of protein induction, cells were harvested and all
protein extraction procedures were performed at 4uC. The cell
pellet was resuspended in l ml lysis buffer (50 mM NaH2PO4,
300 mM NaCl, 10 mM imidazole, pH 8.0) and stored at 220
uC overnight. The cells were then sonicated, centrifuged and
the supernatant containing the soluble proteins was collected.
Table 2. Primer sequences used for amplification of the 12 predicted ORFs of Burkholderia pseudomallei OmpA.
Sanger ID Designation Forward sequence Reverse sequence
BPSL0999 Omp1 .59caccatgaataccaaaa ,59ctgcgccgcttgc
BPSL3099 Omp2 .59caccatgcgcaaaacgac ,59ctgtcccgcgcggaattc
BPSL2522 Omp3 .59caccatgaataaactttcaaagctc ,59ctgcgccggaacggtcgtc
BPSL2062 Omp4 .59caccatgttcaagac ,59cgctccgtcgagccccgc
BPSL1659 Omp5 .59caccatgaattctactaacg ,59cttttgcttgatgcggatttc
BPSS0096 Omp6 .59caccatgtcgcgtcagattc ,59tgatcccgtaccgctcgccttcctg
BPSL2765 Omp7 .59caccatgaccacaaggag ,59ctgttgatagacgagg
BPSS0102 Omp8 .59caccatgaattcgggc ,59cagcgtgaccgcgatttcga
BPSS0909 Omp9 .59caccatgaacaggatgtcgaaata .59gcgccgttcgccggcgacgtc
BPSS1264 Omp10 .59caccatgtcggtgctgctc ,59tccacgacgctcaccg
BPSS0168 Omp11 .59caccatgcccgagcgg ,59gcgcgcgaccgtgatttc
BPSS0531 Omp12 .59caccatgctcgatcgcg ,59tggctgacggccctccgtggtcgg
doi:10.1371/journal.pone.0006496.t002
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the Ni-NTA purification system (QIAgen, USA). The column was
washed with wash buffer (50 mM NaH2PO4, 300 mM NaCl,
20 mM imidazole, pH 8.0) and then protein fractions were eluted
with elution buffer (50 mM NaH2PO4, 300 mM NaCl, 250 mM
imidazole, pH 8.0). The eluted protein fractions were concentrat-
ed by centrifugation (Vivaspin, MW cutoff 10 kDa) (Vivascience,
Germany) and protein concentration was determined using the
bicinchoninic acid assay (BCA) (Sigma, USA) [35].
Electrophoresis and Western blotting
Sodium dodecyl sulphate polyacrylamide gel electrophoresis
(SDS-PAGE) was carried out according to Laemmli [36] using a
12% polyacrylamide gel. Protein samples (30 mg) were separated
under reducing conditions and subsequently transferred to a
nitrocellulose membrane (Amersham, USA) [37] and subjected to
Western blotting with anti-His (C-term) HRP antibody (Invitro-
gen, USA) (dilution 1:3000) and detected using SuperSignalH West
Pico chemiluminescent HRP substrate (Pierce, USA). Recombi-
nant proteins were also probed with rabbit anti-B. pseudomallei sera
(see below) (dilution 1:5000), pooled melioidosis patients’ sera
(dilution 1:1600) or pooled patients’ sera with Legionella infection
(B. pseudomallei-negative) followed by goat anti-rabbit IgG conju-
gated with HRP (Promega, USA) (dilution 1:10,000) or anti-
human antibody IgG with HRP (Sigma, USA) (dilution 1:4000)
respectively, and signals were detected as above.
Human sera samples
Culture-confirmed melioidosis sera of five adult patients from
Malaysia presenting with acute and chronic disease manifestations
were pooled and used. The serum samples from two patients
presenting with Legionella infection but confirmed B. pseudomallei-
negative were pooled and used as the control. A series of dilutions
was performed on the serum samples to determine the optimal
titres for Western analysis. All the serum samples were generously
provided by the Institute for Medical Research, Malaysia.
Rabbit anti-B. pseudomallei serum
Rabbit anti-serum was raised against heat killed (80uC, 1 h)
whole B. pseudomallei cells. Heat-treated cells were injected into two
male New Zealand White rabbits. The first rabbit received
5610
5 cfu in Freund’s incomplete adjuvant (FIA) while the second
rabbit received 2.5610
5 cfu in FIA, respectively, for 2-week
intervals over 2 doses. Rabbits were bled 2 weeks after the second
dose and sera samples were collected. ELISA was performed
according to the protocol described elsewhere [38] using heat-
killed whole B. pseudomallei cells to test the sera reactivity and
calculate the optimal titre for immunoblotting.
Antibody analysis and mouse protection study
BALB/c mice (n=4, 6 weeks, female) were immunised with
three doses of 50 mg purified recombinant Omp3 or Omp7, via
the intraperitoneal route (i.p.) over 9 weeks. The first dose was
administered in Freund’s complete adjuvant (FCA) while the latter
two doses were in FIA, three weeks apart. For antibody analysis,
the sera samples were collected (n=4) prior to immunisation one
week after the second booster and pooled. The antibody titre of
total IgG was analysed by ELISA as previously described [38].
Briefly, the 96-well microplates were coated with 0.5 mg per well of
either purified recombinant Omp3 or Omp7, or crude E. coli
protein in coating buffer (0.1 M sodium bicarbonate, p.H 8.6) and
incubated overnight at 4uC. The plates were blocked, washed,
then incubated with serial dilutions of sera samples and incubated
at 37uC for 1 h. The diluted Rabbit anti-mouse IgG conjugated
with peroxidase (1:4000, Pierce, USA) was added and incubation
continued for 1 h at 37uC. At the end of the incubation, the plates
were washed and 1-step
TM Ultra TMB-ELISA (Pierce, USA) was
added as substrate. The reaction solutions were read at 450 nm
using a microplate reader.
For detection of Omp3 and Omp7 polyclonal antibody isotypes,
plates coated with recombinant Omps were probed with mouse
sera as primary antibodies followed by the addition of specific anti-
mouse IgG1-, IgG2a-, IgG2b- or IgM-HRP conjugated secondary
antibodies (1:1000 for IgG, and 1:2000 for IgM) (Zymed, CA,
USA).
The LD50 of the B. pseudomallei local isolate D286 via an i.p.
route of infection was previously calculated at approximately
1610
5 cfu in a BALB/c mouse model (data not shown). Thus,
1610
6 cfu (106LD50) were used in this study as the lethal dose for
infection. Mice were challenged intraperitoneally 2 weeks after the
second booster with approximately 1610
6 cfu B. pseudomallei
D286. Mice were examined daily for 21 days post-challenge.
Control mice (n=3) received E. coli BL21 (DE3) cells in FIA
followed by challenge.
Statistical analysis
Statistical analysis on anti-OmpA mice sera reactivity was
performed using the Mann Whitney test within the SPSS (version
14.0) software package. Data are expressed as the mean6SEM.
Survival (%) was calculated using the Kaplan-Meier Cumulative
Survival Plot for Time (nonparametric survival analysis) and
survival curves were compared using Log Rank tests (GraphPad
Prism) where P values of ,0.05 were taken to be significant. All
experiments were replicated in a comparable fashion and found to
produce findings similar to the data presented. The median
survival is defined as the time at which half the subjects have died.
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